Kindred Capital — 2024 Investments
1 investments dated 2024 · listed companies and verified rows first · show all
Shift Bioscienceshiftbioscience.comin𝕏Oct 2024 · $16M
Shift Bioscience develops siRNA therapeutics for cell rejuvenation, using a target identification platform that has identified an anti-fibrotic candidate initially aimed at liver fibrosis.
AI & Machine LearningBiotechLongevityCambridge, GB
Daniel Ives(Founder & CEO)Brendan Swain(Co-founder & CSO)
Co-investorsF-Prime Capital
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.